Details of the Drug

General Information of Drug (ID: DMSWNJF)

Drug Name

Ravulizumab

Synonyms

Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210

Indication

Disease Entry	ICD 11	Status	REF
Paroxysmal nocturnal haemoglobinuria	3A21.0	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[2]
------------------------------------------------------------------------------------

Drug Type

Antibody

Sequence

>A chain
XVQLVQSGAEVKKPGASVKVSCKASGHIFSNYWIQWVRQAPGQGLEWMGEILPGSGHTEY
TENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTV
SSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQE
GNVFSCSVLHEALHSHYTQKSLSLSLG
>B chain
DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

ADMET Property

Clearance: The clearance of drug is 0.08 L/day []
Half-life: The concentration or amount of drug in body reduced by one-half in 49.7 +/- 8.9 days []
Vd: The volume of distribution (Vd) of drug is 5.34 L []

Cross-matching ID

DrugBank ID: DB11580
TTD ID: D0NW7Y

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement C5 (CO5)	TTKANGO	CO5_HUMAN	Inhibitor	[1]
HUMAN complement C5 protein (C5)	TTN0GJ5	CO5_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Paroxysmal nocturnal haemoglobinuria

ICD Disease Classification

3A21.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Complement C5 (CO5)	DTT	C5	7.69E-01	-0.12	-0.23

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	ClinicalTrials.gov (NCT04369469) Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia. U.S. National Institutes of Health.
3	Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23.